Record Details

DABIGATRAN ETEXILATE FOR THE TREATMENT OF VENOUS THROMBOEMBOLIC COMPLICATIONS

Atherothrombosis Journal

View Archive Info
 
 
Field Value
 
Title DABIGATRAN ETEXILATE FOR THE TREATMENT OF VENOUS THROMBOEMBOLIC COMPLICATIONS
ВОЗМОЖНОСТИ ДАБИГАТРАНА ЭТЕКСИЛАТА В ЛЕЧЕНИИ ВЕНОЗНЫХ ТРОМБОЭМБОЛИЧЕСКИХ ОСЛОЖНЕНИЙ
 
Creator N. Vorobieva M.; Russian Cardiology Research and Production Complex FGBU of the Ministry of Health of the Russian Federation, Moscow
E. Panchenko P.; Russian Cardiology Research and Production Complex FGBU of the Ministry of Health of the Russian Federation, Moscow
Н. ВОРОБЬЕВА М.
Е. ПАНЧЕНКО П.
 
Subject —
венозные тромбоэмболические осложнения;тромбоз глубоких вен;тромбоэмболия легочной артерии;дабигатран;варфарин;антикоагулянты
 
Description This article discusses the significant features and use of new oral anticoagulant dabigatran etexilate for the treatment of venous thromboembolic complications (VTC). The article presents the results of 4 randomized clinical studies: RE-COVER, RE-COVER II, RE-MEDY and RESONATE. The RE-COVER and RE-COVER (II) studies compared the effectiveness and safety of dabigatran and warfarin in patients with acute episode of VTC, and RE-MEDY and RESONATE studies assessed the prolongation of dabigatran therapy in patients with VTC, who completed the main 3-6-month course of anticoagulant therapy. In addition, REMEDY study estimated efficacy of dabigatran compared with warfarin, and RE-SONATE study estimated one compared with placebo. RE-COVER, RE-COVER II and RE-MEDY showed that the efficacy of dabigatran (150 mg 2 times a day) for the prevention of recurrent and fatal episodes of VTС was not less than that of warfarin; on top of that, dabigatran was more efficient in reducing the risk of hemorrhag-ic complications. In RE-SONATE study, dabigatran showed a 92% reduction in risk of the VTC relapse compared to placebo, but a 2.9-fold increase in risk of large or small clinically significant bleeding.
В данной статье обсуждаются возможности использования нового перорального антикоагулянта — дабигатрана этексилата — для лечения венозных тромбо-эмболических осложнений (ВТЭО). Представлены результаты 4 рандомизированных клинических исследований — RE-COVER, RE-COVER II, RE-MEDY и RE-SONATE. В RE-COVER и RE-COVER II сравнили эффективность и безопасность дабигатрана и варфарина у больных с острым эпизодом ВТЭО, а в REMEDY и RE-SONATE оценили целесообразность продления терапии дабигатра-ном у больных ВТЭО, завершивших основной 3—6-месячный курс лечения антикоагулянтами. При этом в RE-MEDY дабигатран сравнили с варфарином, а в RE-SONATE — с плацебо. По итогам RE-COVER, RE-COVER II и RE-MEDY эффективность дабигатрана (150 мг 2 раза в день) в отношении предупреждения рецидивирующих и фатальных эпизодов ВТЭО не уступала таковой варфарина, а по влиянию на риск геморрагических осложнений дабигатран оказался более безопасным. В исследовании RE-SONATE по сравнению с плацебо дабигатран снижал риск рецидива ВТЭО на 92%, но увеличивал при этом риск больших или клинически значимых малых кровотечений в 2,9 раза.
 
Publisher «REMEDIUM GROUP» Ltd.
 
Contributor —
—
 
Date 2016-05-31
 
Type info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
—
 
Format application/pdf
 
Identifier http://www.aterotromboz.ru/jour/article/view/44
10.21518/2307-1109-2015-2-17-31
 
Source Atherothrombosis Journal; № 2 (2015); 17-31
Атеротромбоз; № 2 (2015); 17-31
2307-1109
10.21518/2307-1109-2015-2
 
Language rus
 
Relation http://www.aterotromboz.ru/jour/article/view/44/70
Oger E. Incidence of venous thromboembolism: a community-based study in Western France. Thromb Haemost, 2000. 83: 657-660.
Spencer FA, Emery C, Lessard D et al. The Worcester Venous Thromboembolism study: a population-based study of the clinical epidemiology of venous thromboembolism.J Gen Intern Med, 2006. 21: 722-727.
Deitelzweig SB, Johnson BH, Lin J, Schulman KL. Prevalence of clinical venous thromboembolism in the USA: current trends and future projections. AmJ Hematol, 2011. 86: 217-220.
Kearon C, Akl EA, Comerota AJ et al. Antithrombotic therapy for VTE disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed.: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest, 2012. 141 (Suppl): e419S-e494S.
Российские клинические рекомендации по диагностике, лечению и профилактике венозных тром-боэмболических осложнений. Флебология, 2010. 4(1): 4-37.
Ansell J, Hirsh J, Hylek E et al. Pharmacology and man-
agement of the vitamin K antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest, 2008. 133 (Suppl): 160S-198S.
Baetz BE, Spinler SA. Dabigatran etexilate: an oral direct thrombin inhibitor for prophylaxis and treatment of thromboembolic diseases. Pharmacotherapy, 2008.28: 1354-1373.
Eriksson BI, Dahl OE, Rosencher N et al. Oral dabigatran etexilate vs. subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: the RE-MODEL randomized trial.J ThrombHaemost, 2007. 5: 2178-2185.
Eriksson BI, Dahl OE, Rosencher N et al. Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double-blind, non-inferiority trial. Lancet, 2007. 370: 949-956.
Connolly SJ, Ezekowitz MD, Yusuf S et al. Dabigatran versus warfarin in patients with atrial fibrillation. N EnglJMed, 2009. 361: 1139-1151.
Graham DJ, Reichman ME, Wernecke M et al. Cardiovascular, Bleeding, and Mortality Risks in Elderly Medicare Patients Treated with Dabigatran or Warfarin for Non-Valvular Atrial Fibrillation. Circulation, published online October 30, 2014. DOI: 10.1161/CIRCULATIONAHA. 114.012061.
Schulman S, Kearon C, Kakkar AK et al. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N EnglJMed, 2009. 361: 2342-2352.
Schulman S, Kearon C. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients.J Thromb Haemost, 2005. 3: 692-694.
Schulman S, Kakkar AK, Goldhaber SZ et al. Treatment of Acute Venous Thromboembolism With Dabigatran or Warfarin and Pooled Analysis. Circulation, 2014. 129: 764-772.
Walenga JM, Adiguzel C. Drug and dietary interactions of the new and emerging oral anticoagulants. Int JClinPract, 2010. 64: 956-967.
Gross PL, Weitz JI. New antithrombotic drugs. Clin Pharmacol Пег, 2009. 86: 139-146.
Rose AJ, Ozonoff A, Henault LE, Hylek EM. Warfarin for atrial fibrillation in community-based practice.J Thromb Haemost, 2008. 6: 1647-1654.
Fiessinger JN, Huisman MV, Davidson BL et al. Ximelagatran vs low-molecular-weight heparin and warfarin for the treatment of deep vein thrombosis: a randomized trial. JAMA, 2005. 293: 681-689.
Schulman S, Wahlander K, Lundstrom T et al. Secondary prevention of venous thromboembolism with the oral direct thrombin inhibitor ximelagatran. NEnglJMed, 2003. 349: 1713-1721.
Ezekowitz MD, Reilly PA, Nehmiz G et al. Dabigatran with or without concomitant aspirin compared with warfarin alone in patients with nonvalvular atrial fibrillation (PETRO Study). AmJCardiol, 2007. 100: 1419-1426.
The EINSTEIN Investigators. Oral rivaroxaban for symptomatic venous thromboembolism. NEnglJMed, 2010.363:2499-2510.
The EINSTEIN-PE Investigators. Oral Rivaroxaban for the Treatment of Symptomatic Pulmonary Embolism. NEnglJMed, 2012. 366: 1287-1297.
Agnelli G, Buller HR, Cohen A et al. AMPLIFY Investigators. Oral Apixaban for the Treatment of Acute Venous Thromboembolism. NEnglJMed, 2013. 369: 799-808.
Hokusai-VTE Investigators. Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism. NEnglJMed, 2013. 369: 1406-1415.
Schafer AI. Venous thrombosis as a chronic disease. N EnglJMed, 1999. 340: 955-956.
Prandoni P, Lensing AW, Cogo A et al. The long-term clinical course of acute deep venous thrombosis. Ann Intern Med, 1996. 125: 1-7.
Agnelli G, Prandoni P, Santamaria MG et al. Three months versus one year of oral anticoagulant therapy for idiopathic deep venous thrombosis. NEnglJMed, 2001.345: 165-169.
Agnelli G, Prandoni P, Becattini C et al. Extended oral anticoagulant therapy after a first episode of pulmonary embolism. Ann Intern Med, 2003. 139: 19-25.
Kearon C, Gent M, Hirsh J et al. A comparison of three months of anticoagulation with extended anti-coagulation for a first episode of idiopathic venous thromboembolism. NEnglJMed, 1999. 340: 901-907.
Schulman S, Kearon C, Kakkar AK et al. for the REMEDY and the RE-SONATE Trails Investigators. Extended Use of Dabigatran, Warfarin, or Placebo in Venous Thromboembolism. NEnglJMed, 2013. 368: 709-718.
Agnelli G, Buller HR, Cohen A et al. for the AMPLIFY-EXT Investigators. Apixaban for Extended Treatment of Venous Thromboembolism. NEnglJMed, 2013. 368: 699-708.
 
Rights Authors who publish with this journal agree to the following terms:Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
Авторы, публикующие в данном журнале, соглашаются со следующим:Авторы сохраняют за собой авторские права на работу и предоставляют журналу право первой публикации работы на условиях лицензии Creative Commons Attribution License, которая позволяет другим распространять данную работу с обязательным сохранением ссылок на авторов оригинальной работы и оригинальную публикацию в этом журнале.Авторы сохраняют право заключать отдельные контрактные договорённости, касающиеся не-эксклюзивного распространения версии работы в опубликованном здесь виде (например, размещение ее в институтском хранилище, публикацию в книге), со ссылкой на ее оригинальную публикацию в этом журнале.Авторы имеют право размещать их работу в сети Интернет (например в институтском хранилище или персональном сайте) до и во время процесса рассмотрения ее данным журналом, так как это может привести к продуктивному обсуждению и большему количеству ссылок на данную работу (См. The Effect of Open Access).